Stockscreener 앱 받기
30.03
5.22%
1.49
시간 외 거래:
30.03
전일 마감가:
$28.54
열려 있는:
$28.18
하루 거래량:
1.04M
Relative Volume:
1.31
시가총액:
$2.00B
수익:
$1.55M
순이익/손실:
$-258.76M
주가수익비율:
-7.7093
EPS:
-3.8953
순현금흐름:
$-213.66M
1주 성능:
+0.50%
1개월 성능:
+27.57%
6개월 성능:
+22.02%
1년 성능:
+50.53%
1일 변동 폭
$27.92
$30.45
1주일 범위
$27.92
$30.93
52주 변동 폭
$14.40
$31.99
Celldex Therapeutics Inc Stock (CLDX) Company Profile
명칭
Celldex Therapeutics Inc
전화
908-200-7500
주소
53 FRONTAGE ROAD, HAMPTON
Compare CLDX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CLDX
Celldex Therapeutics Inc
|
30.03 | 1.90B | 1.55M | -258.76M | -213.66M | -3.8953 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-21 | 개시 | Mizuho | Outperform |
| 2025-10-13 | 개시 | Barclays | Underweight |
| 2025-04-28 | 개시 | Canaccord Genuity | Buy |
| 2025-03-20 | 개시 | Morgan Stanley | Overweight |
| 2025-02-13 | 개시 | UBS | Buy |
| 2024-10-07 | 개시 | Citigroup | Buy |
| 2024-09-30 | 개시 | Goldman | Neutral |
| 2024-09-27 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-06-18 | 개시 | Stifel | Buy |
| 2024-06-11 | 개시 | Wolfe Research | Outperform |
| 2023-12-20 | 개시 | TD Cowen | Outperform |
| 2023-11-10 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2023-08-22 | 개시 | Wells Fargo | Underweight |
| 2021-09-17 | 개시 | Jefferies | Buy |
| 2021-09-10 | 개시 | SVB Leerink | Outperform |
| 2021-07-22 | 개시 | Guggenheim | Buy |
| 2020-02-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-08-01 | 재개 | H.C. Wainwright | Buy |
| 2016-11-07 | 개시 | Aegis Capital | Buy |
| 2016-03-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2016-03-07 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2016-03-07 | 다운그레이드 | Leerink Partners | Outperform → Mkt Perform |
| 2016-03-07 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2016-03-01 | 개시 | H.C. Wainwright | Buy |
| 2015-08-11 | 재확인 | Brean Capital | Buy |
| 2015-08-11 | 재확인 | Oppenheimer | Outperform |
| 2015-08-11 | 재확인 | ROTH Capital | Buy |
| 2015-06-02 | 재확인 | WBB Securities | Strong Buy |
| 2014-11-17 | 재확인 | ROTH Capital | Buy |
| 2014-03-04 | 재확인 | Oppenheimer | Outperform |
| 2013-07-08 | 재확인 | Cantor Fitzgerald | Buy |
| 2013-03-08 | 재확인 | Cantor Fitzgerald | Buy |
| 2013-02-26 | 재확인 | Oppenheimer | Outperform |
| 2013-01-10 | 재확인 | Cantor Fitzgerald | Buy |
| 2012-10-02 | 재확인 | Oppenheimer | Outperform |
| 2012-09-14 | 재확인 | Cantor Fitzgerald | Buy |
모두보기
Celldex Therapeutics Inc 주식(CLDX)의 최신 뉴스
Breakout Zone: Can Celldex Therapeutics Inc reach all time highs this year2026 Action & Low Volatility Stock Recommendations - baoquankhu1.vn
Assessing Celldex Therapeutics (CLDX) Valuation After Recent Share Price Momentum - Sahm
Eventide Asset Management LLC Has $48.10 Million Stock Holdings in Celldex Therapeutics, Inc. $CLDX - MarketBeat
Celldex Therapeutics, Inc. $CLDX Shares Sold by Commodore Capital LP - MarketBeat
Braidwell LP Makes New Investment in Celldex Therapeutics, Inc. $CLDX - MarketBeat
Celldex Therapeutics (CLDX) Stock Analysis Report | Ratings, Financials & Performance - Benzinga Japan
Celldex Therapeutics Touts Barzolvolimab Phase III CSU Momentum, Lays Out 2026 Data Catalysts - MarketBeat
Insider Sell: Does Celldex Therapeutics Inc stock benefit from AI growth2026 Reactions & Smart Money Movement Tracker - baoquankhu1.vn
Celldex Therapeutics (CLDX) Is Up 5.7% After New Phase 2 Barzolvolimab Data in Inducible Urticaria - Sahm
Chronic Spontaneous Urticaria Pipeline Expands with 25+ - openPR.com
Chronic Spontaneous Urticaria Pipeline Expands with 25+ Therapies and 20+ Companies Advancing Next-Generation Treatments by 2026 | DelveInsight - Barchart
CLDX: Barzolvolimab shows strong efficacy in CSU, with key phase 3 data expected in Q4 - TradingView
Celldex Therapeutics, Inc. $CLDX Shares Purchased by American Century Companies Inc. - Defense World
Celldex Therapeutics Highlights Barzolvolimab Phase 3 Wins, New Trials at TD Cowen Conference - Defense World
Celldex Therapeutics stock hits 52-week high at $31.36 By Investing.com - Investing.com South Africa
Celldex Therapeutics (NASDAQ:CLDX) Sets New 12-Month HighStill a Buy? - MarketBeat
Celldex Therapeutics stock hits 52-week high at $31.36 - Investing.com
A Look At Celldex Therapeutics (CLDX) Valuation After New Barzolvolimab Urticaria Data - Sahm
Fund Flows: Can Celldex Therapeutics Inc keep up with sector leadersJuly 2025 Trade Ideas & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Market Outlook: Will Celldex Therapeutics Inc benefit from geopolitical trends2025 Dividend Review & Precise Swing Trade Alerts - baoquankhu1.vn
New Barzolvolimab Urticaria Data And Losses Might Change The Case For Investing In Celldex Therapeutics (CLDX) - Sahm
TD Asset Management Inc Decreases Stake in Celldex Therapeutics, Inc. $CLDX - MarketBeat
Propel Bio Management LLC Makes New $4.01 Million Investment in Celldex Therapeutics, Inc. $CLDX - MarketBeat
Volatility Watch: Will Celldex Therapeutics Inc benefit from government policyTrade Performance Summary & High Conviction Buy Zone Picks - baoquankhu1.vn
CLDX SEC FilingsCelldex Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Segall Bryant & Hamill LLC Buys 140,709 Shares of Celldex Therapeutics, Inc. $CLDX - MarketBeat
Fisher Asset Management LLC Acquires 104,949 Shares of Celldex Therapeutics, Inc. $CLDX - MarketBeat
Celldex Therapeutics, Inc. (CLDX) Stock Analysis: Exploring an 83.57% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
The Goldman Sachs Group Increases Celldex Therapeutics (NASDAQ:CLDX) Price Target to $34.00 - MarketBeat
Q3 Earnings Forecast for CLDX Issued By HC Wainwright - MarketBeat
Celldex Presents Positive Data Demonstrating Barzolvolimab - GlobeNewswire
Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Dis - Yahoo Finance
Celldex Therapeutics, Inc. (CLDX): A Bull Case Theory - Insider Monkey
Assessing Celldex Therapeutics (CLDX) Valuation After Positive Barzolvolimab Phase 3 Enrollment And Phase 2 Data - simplywall.st
Celldex Stock Pre-Market (-4.7%): Profit-Taking After Positive Phase 2 Data Presentation - Trefis
Is Celldex Therapeutics (CLDX) Pricing Reflecting Recent 46% One-Year Surge And DCF Upside Potential - Yahoo Finance
Celldex presents phase 2 data for chronic urticaria treatment By Investing.com - Investing.com Canada
Celldex Presents Additional Positive Data from Phase 2 - GlobeNewswire
What is HC Wainwright's Forecast for CLDX Q1 Earnings? - MarketBeat
Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile - GlobeNewswire
CLDX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Celldex Therapeutics (NASDAQ:CLDX) Announces Quarterly Earnings Results - MarketBeat
Celldex Therapeutics Rallied 24% After Clinical Update: Here’s What Analysts See Next - TIKR.com
Celldex Therapeutics stock earns 88 RS rating - MSN
Celldex Therapeutics Hits Day High with 24% Surge in Stock Price - Markets Mojo
Celldex Therapeutics Hits New 52-Week High at $31.00 - Markets Mojo
Celldex Therapeutics stock hits 52-week high at 30.66 USD By Investing.com - Investing.com India
November 20th Options Now Available For Celldex Therapeutics (CLDX) - Nasdaq
Celldex Therapeutics (NASDAQ:CLDX) Receives Buy Rating from Stifel Nicolaus - MarketBeat
Celldex Therapeutics (NASDAQ:CLDX) Hits New 52-Week HighHere's What Happened - MarketBeat
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Celldex Therapeutics Inc (CLDX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):